Palisade Bio, INC 8-K filings

Palisade Bio announced second quarter 2026 financial results, highlighting the advancement of its lead drug candidate PALI-2108 into Phase 2 development for inflammatory bowel disease and a strong cash position.

Palisade Bio appointed Jordan Zwick to its Board of Directors and received stockholder approval to increase authorized common stock to 450 million shares.

Palisade Bio announced first quarter 2026 financial results, highlighting progress in its PALI-2108 clinical program for inflammatory bowel disease and a strong cash position.

Palisade Bio has entered into a master services agreement with Iterative Health and raised $3 million through a private placement of common stock to support its PALI-2108 Phase 2 study.

Palisade Bio stockholders approved an increase in authorized common stock and the issuance of shares underlying warrants at a special meeting.

Palisade Bio, Inc. announced the termination of its Phantom Unit Plan, resulting in the forfeiture of unvested awards for key executives.

Palisade Bio, Inc. stockholders approved a reverse stock split, elected three directors, and ratified Baker Tilly US, LLP as their independent auditor at the annual meeting.

Palisade Bio, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement and reported approximately $133.3 million in cash and cash equivalents.

Palisade Bio, a clinical-stage biopharmaceutical company, announced the cancellation of its special stockholder meeting due to a persistent lack of quorum, withdrawing previously proposed items.

Palisade Bio, Inc. adjourned its special stockholder meeting due to a lack of quorum, rescheduling it for October 10, 2025.

Palisade Bio, Inc. adjourned its special stockholder meeting due to a lack of quorum, rescheduling it for September 26, 2025.

Palisade Bio, Inc. has adopted a new Phantom Unit Plan and updated executive employment agreements, enhancing long-term incentive and severance provisions for key personnel.

Palisade Bio, Inc. has entered into an agreement with an institutional holder to exercise existing warrants at a reduced price, generating $3.9 million in gross proceeds, and issuing new warrants for additional shares.

Palisade Bio, Inc. announced the appointment of Dr. Emil Chuang, a seasoned pediatric gastroenterologist with extensive pharmaceutical and clinical development experience, to its Board of Directors, following the amicable resignation of Margery Fischbein.

Palisade Bio, Inc. received a notice from Nasdaq on April 30, 2025, indicating that its common stock has traded below the minimum bid price of $1.00 for 30 consecutive trading days, potentially leading to delisting.

Palisade Bio successfully closed a $5 million underwritten public offering, which included the repricing of existing warrants and the issuance of new common stock and warrants.

Palisade Bio, Inc. has entered into a revised employment agreement with its CEO and CFO, J.D. Finley, maintaining his base salary and bonus structure while outlining severance and change-in-control benefits.

Palisade Bio held its annual meeting on July 8, 2024, where stockholders elected three directors and ratified the selection of Baker Tilly US, LLP as the independent accounting firm.

Palisade Bio has appointed Margery Fischbein, a seasoned healthcare investment banker, to its Board of Directors, effective May 7, 2024.

Palisade Bio has entered into a definitive agreement for a $4 million private placement, priced at-the-market under Nasdaq rules, to fund working capital and general corporate purposes.

Palisade Bio presented an update on their PALI-2108 program for ulcerative colitis at the IBD Innovate conference, highlighting its progress towards a Phase 1 clinical study.

Palisade Bio has enacted a 1-for-15 reverse stock split to increase its share price and comply with Nasdaq's minimum listing requirements.

Palisade Bio announced its 2023 financial results, highlighted by a net operating loss of $13.1 million, and provided a corporate update, including the advancement of its lead program PALI-2108 towards a Phase 1 clinical study.

Palisade Bio, Inc. has amended its bylaws to eliminate its classified board structure, moving to annual elections for all directors.

Palisade Bio announces a strategic board restructuring and progress in the development of its lead drug candidate, PALI-2108, for ulcerative colitis.

Palisade Bio has entered into agreements with accredited investors to exercise existing warrants, generating approximately $2.5 million in gross proceeds and issuing new replacement warrants.

Palisade Bio announced positive preclinical data for its lead asset, PALI-2108, a novel oral PDE4 inhibitor prodrug for ulcerative colitis, at the 2024 Crohn's & Colitis Congress.